ÂÜÀòÂÒÂ×

Craig’s background includes nearly three decades of experience across interconnected health, life science and technology markets – including biotech, biopharma, devices, diagnostics, health IT, analytics, digital health, and healthcare. His expertise spans strategy, branding, positioning, corporate communications, market development, pipeline/product communication, digital influence, advocacy and policy, working with virtually every health system stakeholder. He serves as chair of the Corporate Alliance and board member for Global Genes (a pan-rare disease organization), is on the board of the Fibrolamellar Cancer Foundation (a rare cancer advocacy group), and is also a co-Founder of RARE-X. He is a commentator and panelist on key issues impacting innovation in health markets and has held leadership positions with consultancies based in Cambridge, Washington, D.C., New York and Brussels.